Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema

Augenabteilung Allgemeines Krankenhaus Linz

Status

Completed

Conditions

Age Related Macular Degeneration

Diabetic Macular Edema

Treatments

Device: Laser speckle flowgraphy

Drug: Intravitreal Aflibercept Injection

Study type

Observational

Funder types

Other

Identifiers

NCT06878573

LSFG-aflibercept-ARMandDME

Details and patient eligibility

About

This prospective study will include patients with neovascular age-related macular degeneration or diabetic macular edema, scheduled for intravitreal aflibercept. Ocular perfusion will be measured by Laser Speckle Flowgraphy (LSFG). The parameter Mean Blur Rate (MBR) reflects erythrocyte flow velocity and serves as an indirect marker of perfusion. MBR will be measured at the optic nerve head (ONH). The devices software can analyze MBR in areas of major retinal vessels (MV) and in microperfusion areas (MT) separately. Measurements will be conducted on the day of the planned intravitreal injection and one and four weeks post-injection.

Enrollment

36 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

age > 50 years,
patients scheduled for an intravitreal injections with Aflibercept for treatment of DME or AMD.

Exclusion criteria

ocular surgery (including intravitreal injection) during the 3 months preceding the study
Ametropia > 6 Dpt
any relevant ophthalmic diseases/conditions that could interfere with LSFG measurements (e.g. glaucoma, optic nerve head drusen, tilted disc, etc.).